All In Biotech

Drug Trial Radar · NCT00634400

Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)

Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function

Last checked: Nov 20, 2026Latest source record: Jan 25, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 6,268 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,268

Planned (sponsor's estimate)

Start

Mar 1999

Primary completion

May 2003

Study completion May 2003

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function

Conditions

  • Congestive Heart Failure

Interventions

  • CandesartanDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cardiovascular mortality or hospitalisation due to congestive heart failureTime frame: 2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.